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Abstract: Several treatment strategies have been proposed in classic lichen planopilaris (LPP), 
although no gold standard therapeutic approach has been recognized so far due to the variable 
and, sometimes, contradictory results reported in the literature, as well as due to the lack of 
guidelines and randomized controlled trials. In the present review, we sought to provide an 
updated overview on the treatment of classic LPP by analyzing the level of evidence of published 
studies, also proposing a possible therapeutic strategy according to the findings highlighted in 
this systematic review.
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Introduction
Lichen planopilaris (LPP) is a relatively uncommon cutaneous disorder characterized 
by a chronic lymphocytic inflammation that leads to the selective destruction of hair 
follicles, thus resulting in scarring alopecia.1 Some authors consider LPP as a follicu-
lar form of lichen planus, although only about 30% of patients present cutaneous or 
mucosal lesions of lichen planus.2
LPP is more common in women than in men (ratio varying from 1.8:1 to 9:1), and 
the peak age of onset is observed between 30 and 60 years.1–4
Although pathogenesis of LPP is still poorly understood, many authors regard such 
a condition as a hair-specific autoimmune disorder in which T-lymphocytes target 
follicular antigens with the consequent destruction of the hair follicle stem cells.1–4 
Possible involved inflammatory mediators include b-FGF and TGF-β, which would be 
responsible for fibroblast activation.1–3 Interestingly, recent evidence has pointed out 
a possible role of PPAR-g in the destruction of the pilosebaceous unit typical of LPP.3
LPP classically presents as follicular keratotic plugs and/or perifollicular scal-
ing along with perifollicular erythema, with subsequent hair loss resulting in patchy 
alopecic areas.1,2 Of note, in acute phases, LPP patients may experience pruritus, 
pain, and/or burning sensation, differently from other primary scarring alopecias.1,2 
Besides classic LPP, there are two main clinical variants, viz. frontal fibrosing alo-
pecia and Graham-Little–Piccardi–Lasseur syndrome, with the former presenting 
with a progressing band of alopecia of the hairline in postmenopausal women and 
the latter being characterized by the triad of scarring patchy alopecia of the scalp, 
nonscarring alopecia of the axillae/pubic region, and spinous follicular papules of 
the trunk/limbs.1,3,4
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The main differential diagnoses of LPP include discoid 
lupus erythematosus, alopecia areata, centrifugal cicatricial 
alopecia, and folliculitis decalvans.1–5 A good physical assess-
ment, along with dermoscopic and histological examination, 
is important to distinguish LPP from such conditions.1–5
From a histological point of view, active lesions show a 
band-like subepidermal lymphocytic infiltrate, “hugging” 
the upper hair follicle (isthmus and infundibulum), with no 
involvement of the deeper portion of the follicle (differently 
from alopecia areata), while late lesions are mainly character-
ized by the reduction/loss of sebaceous glands and of arrector 
pili muscles, concentric perifollicular fibrosis, and irrevers-
ible destruction of the follicle with perifollicular hyaliniza-
tion in both upper/lower dermis and follicular tract.2–4 Other 
specific histological features include mucinous perifollicular 
fibroplasia in the upper dermis, the absence of interfollicular 
mucin, and a superficial perifollicular wedge-shaped scar-
ring.2–4 In 40% of cases, direct immunofluorescence shows 
colloid bodies and/or positive staining for immunoglobulin 
M (IgM) and, less commonly, IgA or C3; a linear band of 
fibrin and/or fibrinogen at the dermoepidermal junction may 
also be present.2–4
The dermoscopy of LPP displays several features, with 
the most specific finding of active lesions being perifollicular 
scaling forming a sort of “collar” on the proximal portion 
of the hair shaft. Late lesions may show fibrotic white dots, 
acquired pili torti, loss of follicular openings, white areas, 
honeycomb/scattered hyperpigmentation, milky red areas, 
and hair tufts.5
Many treatment strategies have been proposed in clas-
sic LPP based on findings from anecdotal case reports, 
case series, or small studies.1–3 However, no gold standard 
therapeutic approach has been recognized so far due to the 
variable and, sometimes, contradictory results reported in 
the literature, as well as due to the lack of guidelines and 
randomized controlled trials.1–3 Besides, there is a lack of 
updated systematic reviews taking into account the level 
of evidence of treatment modalities for classic LPP. In this 
review, we sought to fill such a gap by providing an updated 
overview analyzing the level of evidence of published studies 
dealing with classic LPP therapies.
Materials and methods
All published information about LPP treatments was retrieved 
by a comprehensive search of the literature using the PubMed 
electronic database; the search term was “lichen planopila-
ris.” A manual search was also carried out by analyzing the 
reference sections of all relevant studies or reviews about 
such a topic. All publications reporting the treatment of at 
least one classic LPP instance were considered, excluding 
frontal fibrosing alopecia, Graham-Little–Piccardi–Lasseur 
syndrome, and LPP exclusively involving areas other than 
scalp, as well as articles not specifying either therapeutic 
response outcome or LPP subtype. Notably, only English 
language papers were included in this review. 
For each included study, reported variables such as author, 
year, the type of treatment, the type of study (classified 
according to standard definitions),6 the number of patients, 
and response outcomes were recorded. In addition, we also 
evaluated the level of evidence available for each considered 
paper, according to the most recent guidelines for evidence-
based medicine, The Oxford 2011 Levels of Evidence:7 level 
of evidence I, systematic review of randomized trials or 
n-of-1 trials; II, randomized trial or observational study with 
dramatic effect; III, nonrandomized controlled cohort/follow-
up study; IV, case series, case–control studies, or historically 
controlled studies; V, mechanism-based reasoning. Notably, 
single case reports were labeled as level of evidence V.
For practical purposes, we will first describe the treat-
ments for which there is good evidence (if any) and then 
mention those having weaker evidence. In case of therapies 
having the same level of evidence, we will first list those with 
the greater number of treated patients.
Results
Table 1 summarizes all the results in detail. Importantly, all 
the following response rates refer to the proportion of patients 
experiencing objective clinical improvement regardless of the 
response degree (as it is not always mentioned in the vari-
ous papers) and/or arrest of hair loss; isolated symptomatic 
improvement was not considered as a positive outcome. For 
details on the response degree, refer to Table 1.
Hydroxychloroquine (highest level of 
evidence: II; total number of patients: 127; 
global response rate: 51.2% [65 of 127]; 
response rate in monotherapy: 51.0% 
[52 of 102])
Several studies investigating the efficacy of antimalarials 
have been published,1,2,8–14 including a randomized clinical 
trial evaluating hydroxychloroquine (400 mg daily) versus 
methotrexate (15 mg weekly) administered for 6 months in 
refractory LPP cases.8 In detail, although hydroxychloroquine 
yielded a significant Lichen Planopilaris Activity Index 
(LPPAI) decrease at months 2 and 4 (compared with baseline 
and month 2, respectively), such a study showed a higher 
efficacy for methotrexate, with a mean decrease in LPPAI 
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at the 6th month of 3.3±2.09 versus 1.51±0.91 (P=0.01).8 
Of note, in the hydroxychloroquine group, only erythema 
(P=0.004) showed a significant improvement at the end of the 
study, while perifollicular erythema, perifollicular scaling, 
spreading, and follicular keratosis did not.8
Besides this comparative analysis, there are other studies on 
the use of antimalarials in LPP.1,2,9–14 In particular, a prospective 
study on 12 patients treated with hydroxychloroquine (400 
mg daily) for 6 months found a good response in three cases 
(although their hair count was in a decreasing number) and 
progression in eight instances; one patient was lost during the 
follow-up.9 Higher success rates (including partial and complete 
responses) with the use of hydroxychloroquine were observed 
in other studies, with figures ranging from 40.1% to 76%.1,10,11 
Conversely, other small case series or single case reports showed 
few results with the same drug, with little or no response.12–14
Methotrexate (highest level of evidence: 
II; total number of patients: 16; global 
response rate: 87.5% [14 of 16]; response 
rate in monotherapy: 87.5% [14 of 16])
The efficacy of methotrexate has mainly been studied in 
the abovementioned randomized clinical trial comparing 
hydroxychloroquine (400 mg daily) versus methotrexate 
(15 mg weekly) administered for 6 months.8 Apart from a 
higher global efficacy over hydroxychloroquine (see above), 
methotrexate also showed significant improvement in all 
the assessed variables, viz. pruritus (P=0.007), erythema 
(P=0.01), perifollicular erythema (P=0.01), perifollicular 
scaling (P=0.08), spreading (P=0.001), and follicular kera-
tosis (P=0.04).8 Only a single LPP case showed no significant 
improvement with methotrexate.11
Topical corticosteroids (highest level of 
evidence: IV; total number of patients: 
128; global response rate: 53.9% [69 of 
128]; response rate in monotherapy: 
53.3% [49 of 92]) and intralesional 
corticosteroids (highest level of evidence: 
IV; total number of patients: 30; global 
response rate: 56.7% [17 of 30]; response 
rate in monotherapy: 50.0% [13 of 24])
Potent topical and intralesional (ie, triamcinolone acetonide) 
steroids are often among the first-line treatments in LPP. 
They have been used either in monotherapy or in associa-
tion with other topical and/or systemic therapies, with vari-
able degrees of success.1,12,15–24 In particular, Lyakhovitsky 
et al reported a low success rate in patients treated with 
topical steroids (three complete responders and five par-
tial responders in 42 patients treated in monotherapy), 
while they observed very good results when steroids were 
administered intralesionally (10 partial responders and one 
complete responder in 15 patients treated in monotherapy).1 
Conversely, Mehregan et al observed a higher success rate 
in patients treated with topical steroids than those treated 
with intralesional steroids (70% [14 of 20] versus 0% [0 of 
7]).12 In addition, Chieregato et al found positive outcomes 
in subjects treated with topical corticosteroids, both alone 
or in association with systemic or topical cyclosporine (with 
an overall success rate of 93.3% – 20 of 30 “good results” 
and six of 30 “mild improvement”).15
Apart from the aforementioned studies, there are many 
reports describing one or few LPP patients undergoing topi-
cal and/or intralesional steroids, with very different results 
(from little-to-no improvement to good results with almost 
resolution of clinical features, with or without some degree 
of hair regrowth).16–24
Pioglitazone (highest level of evidence: 
IV; total number of patients: 65; global 
response rate: 66.2% [43 of 65]; response 
rate in monotherapy: 72.3% [34 of 47])
Pioglitazone (dose of pioglitazone: 15 mg/day) has been 
reported as having encouraging results in LPP, with two stud-
ies reporting positive outcomes in the majority of patients, 
viz. five patients with remission and 12 experiencing some 
improvement in one analysis25 and marked improvement in 
16 patients in the other study.26
Less positive findings were observed in a prospective 
observational study on 22 patients treated with pioglitazone 
along with another treatment (refer Table 1 for details), with 
two remissions, seven patients experiencing clinical improve-
ment and nine experiencing failures.27
Symptoms relief and decrease in inflammation at 
2-month and 6-month follow-ups were also observed in a 
multiresistant case treated with pioglitazone (15 mg/day) 
for 8 months.14
Mycophenolate mofetil (highest level of 
evidence: IV; total number of patients: 33; 
global response rate: 48.5% [16 of 33]; 
response rate in monotherapy: 48.5% 
[16 of 33])
Evidence from a retrospective chart analysis of an open-label 
trial including 16 LPP recalcitrant instances treated with 
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mycophenolate mofetil (0.5 mg twice daily for 4 weeks and 
then 1 g twice daily for at least 20 weeks) showed a complete 
response (reduction in baseline LPPAI >85%) in five patients, 
a partial response (reduction in baseline LPPAI ranging from 
25% to 85%) in a further five patients, and treatment failure 
(reduction in baseline LPPAI <25%) in two subjects; four 
patients withdrew from the study because of adverse events.28
Lower figures were observed in a retrospective study on 
10 patients treated with mycophenolate mofetil (2–6 g/day 
for 3–6 months), with only 30% of them showing improve-
ment.11 Similar success rate (40%) was found in another 
study in which the drug was used at the dosage of 2 g daily 
for 2–8 months.2
Finally, a single case report described a complete remis-
sion with the use of mycophenolate mofetil at the dose of 500 
mg twice daily for 6 months without recurrence at 3-month 
follow-up.29 No effect was observed in another case report.14
Oral tetracyclines (level of evidence: 
IV; total number of patients: 30; global 
response rate: 27.6% [8 of 29]; response 
rate in monotherapy: 31.6% [6 of 19])
In a retrospective study on 15 patients treated with oral 
doxycycline (200 mg/day for 3–6 months in monotherapy), 
Spencer et al observed that four of 15 (27%) subjects expe-
rienced positive results, while the rest of the cases had no 
improvement.11
Similar results were found by Lyakhovitsky et al, who 
observed that three of 11 patients treated with an unspecified 
oral tetracycline showed a partial response, whereas the other 
seven cases had no response.1
Three further single reports have been reported, with 
two instances showing failure12,14 and one case displaying 
partial response.24
Cyclosporine (highest level of evidence 
IV; total number of patients: 22; global 
response rate: 77.3% [17 of 22]; response 
rate in monotherapy: 72.2% [13 of 18])
Cyclosporine is another common treatment for LPP.2,12,13,15,18,21 
A small prospective study on 13 subjects treated with oral 
cyclosporine (4–5 mg/kg/day for 4–6 months) showed clini-
cal response in 10 cases; relapse rate was between 60% and 
80%, respectively, 6 months and 12 months after treatment 
discontinuation.2
In addition, several other small case series and single 
case reports on the use of oral cyclosporine have been 
published, with most of them showing good outcomes, 
but also a significant likelihood of relapse after treatment 
discontinuation.12,13,15,18,21
Oral retinoids (highest level of evidence: 
IV; total number of patients: 13; global 
response rate: 23.1% [3 of 13]; response 
rate in monotherapy: 22.2% [2 of 9])
Three small case series have investigated the effect of oral 
retinoids on classic LPP, with three of a total of 13 patients 
displaying positive outcomes.1,2,11
Oral steroids (highest level of evidence: 
IV; total number of patients: 15; global 
response rate: 73.3% [11 of 15]; response 
rate in monotherapy: 71.4% [10 of 14])
Results with oral steroids are generally good,1,12,14,19,24 with the 
largest study (11 patients) investigating their efficacy in LPP 
showing a success rate of 82%.12 However, it is also true that 
the likelihood of relapsing is very high, with 80% of patients 
experiencing a relapse within 1 year after drug withdrawal.12 
Such a trend is confirmed by single case reports reported in 
the literature.1,14,19,24
Griseofulvin (highest level of evidence: 
IV; total number of patients: 12; global 
response rate: 41.7% [5 of 12]; response 
rate in monotherapy: 45.5% [5 of 11])
In a study on ten LPP patients treated with oral griseofulvin 
(dose, frequency, and treatment duration not specified), Meh-
regan et al observed that 50% of cases showed improvement.12
Two further LPP instances treated with griseofulvin have 
been reported, with no significant results in monotherapy30 
or in association with other treatments.19
Topical calcineurin inhibitors (highest 
level of evidence: IV; total number of 
patients: 12; global response rate: 23.1% 
[2 of 12]; response rate in monotherapy: 
11.1% [1 of 9])
Results with topical calcineurin inhibitors are generally 
disappointing, with the largest study (ten patients) dealing 
with the usefulness of such a therapy in LPP displaying par-
tial improvement in inflammation in only two cases (one in 
monotherapy and one associated with hydroxychloroquine).1 
Besides this study, there are also another two case reports 
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about the use of topical calcineurin inhibitors in LPP, showing 
little improvement.17,31
Thalidomide (highest level of evidence: 
IV; total number of patients: 9; global 
response rate: 11.1% [1 of 9]; response 
rate in monotherapy: 11.1% [1 of 9])
Although positive outcomes have been described in a single 
case report,32 two case series, respectively, involving four 
patients (each) showed no significant improvement with a 
dose of thalidomide of 100 mg/day for 6 months2 or 100 
mg/day for 1 month and then 200 mg/day for a further 
6 months.33
Laser therapy (highest level of evidence: 
IV; total number of patients: 13; global 
response rate: 23.1% [3 of 13]; response 
rate in monotherapy: 23.1% [3 of 13])
A case series of 13 patients treated with 308-nm excimer 
laser showed an improvement in three patients and no effect 
in the remaining 10 subjects.34
Discussion
Therapeutic aims in LPP mainly consist of reducing pos-
sible associated symptoms and halting disease activity, 
thereby preventing the development of further alopecic 
areas.1,2 However, being a relatively rare disease, literature 
data on the treatment of LPP are quite sparse, and no gold 
standard approach exists.1,2 Consequently, LPP treatment in 
daily clinical practice often relies on physician’s personal 
experience, although some authors have proposed possible 
therapeutic strategies.1,2 In particular, topical steroids are 
often reported as a first-line treatment (particularly for limited 
cases), especially the ultrapotent corticotherapy clobetasol 
propionate.2 A proposed protocol consists of using such a 
type of topical steroid twice daily for the first month, followed 
by an application once a day for 3 months, and then every 
other day for 3 more months.2 Although some authors have 
advocated the use of systemic oral corticosteroid therapy 
as a second-line treatment (prednisone 1 mg/kg/day for 15 
days, tapered over 4 months), the very high degree of relapse 
(around 80% of patients) after treatment suspension makes 
such a therapy little useful in the long-term period.2 For this 
reason, other authors suggested to administer oral hydroxy-
chloroquine (usually 200 mg twice daily) as initial systemic 
therapy, which may be switched to cyclosporine (3–5 mg/
kg/d) if manifestations continue after 2–4 months of treat-
ment.1,2 However, cyclosporine is commonly characterized 
by both a high relapse rate (60%–80% after 6–12 months 
from withdrawal) and relevant side effects over a long-term 
period.1,2 Because of such reasons, mycophenolate mofetil 
has been proposed as a possible and preferable alternative 
to cyclosporine due to the safer adverse effect profile.2 For 
recalcitrant LPP instances, other therapies have been consid-
ered, including oral retinoids, oral tetracycline, methotrexate, 
griseofulvin, thalidomide, laser therapy, topical calcineurin 
inhibitors, and pioglitazone.1,2
Importantly, the abovementioned treatment strategies are 
not the result of evidence-based therapeutic guidelines, thus 
making their validity quite questionable. In fact, according to 
the present review, there is only one study with a high level 
of evidence, namely a randomized clinical trial (level of evi-
dence: II) comparing hydroxychloroquine and methotrexate 
for a 6-month period in recalcitrant LPP. Interestingly, this 
study revealed not only a significant superiority of metho-
trexate over hydroxychloroquine, but also the very limited 
response of recalcitrant LPP to the latter medication (efficacy 
only on erythema degree), differently from methotrexate 
which showed efficacy on pruritus as well as on all the objec-
tive variables assessed in the study (erythema, perifollicular 
erythema, perifollicular scaling, spreading, and follicular 
keratosis). However, it is noteworthy to emphasize that the 
use of hydroxychloroquine in LPP is not always unsuccessful 
as there are several reports showing positive results, with a 
response rate in monotherapy of 51.0% considering all the 
cases reported in the literature. It is possible to speculate 
that the negative outcomes observed in the abovementioned 
clinical trial could be due to the fact that it was focused only 
on recalcitrant cases.
According to our review, the efficacy of other commonly 
used/suggested therapies, including topical/intralesional/
oral steroids, oral cyclosporine, and oral mycophenolate 
mofetil, is based only on studies with low level of evidence 
(case series and case reports – level of evidence: IV). Such 
therapies have been reported to be useful in classic LPP, 
with an overall response rate in monotherapy of 53.3%, 
50.0%, 71.4%, 72.2%, and 48.5% for topical steroids, 
intralesional steroids, oral steroids, oral cyclosporine, and 
oral mycophenolate mofetil, respectively. Obviously, topi-
cal/intralesional steroids are more suitable for cases with 
limited involvement, while oral steroids, oral cyclosporine, 
and oral mycophenolate mofetil are commonly suggested 
for extensive forms. However, as previously stated, use of 
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both oral steroids and cyclosporine are characterized by a 
high relapse rate after their suspension as well as significant 
side effects in the case of prolonged administration, thus 
making oral mycophenolate mofetil a better choice over a 
long-term period.
Similarly, the level of evidence available for all the 
other treatments reported in the literature is low (case series 
and/or single case reports – level of evidence: IV/V), with 
the following response rates (in monotherapy): 31.6% for 
oral tetracyclines, 72.3% for pioglitazone, 23.1% for laser 
therapy, 22.2% for oral retinoids, 45.5% for griseofulvin, 
11.1% for topical calcineurin inhibitors, and 11.1% for 
thalidomide. 
Based on previously suggested therapeutic strategies, 
drug safety profiles/manageability, and the level of evi-
dence/success rates highlighted in this systematic review, 
it is possible to speculate that topical/intralesional steroids 
and hydroxychloroquine might be a reasonable first-line 
therapy in localized and extensive classic LPP cases, 
respectively. In the case of topical/intralesional steroids 
resistance and progressive course, patients with localized 
forms may be switched to hydroxychloroquine. When 
experiencing therapy failure with hydroxychloroquine, 
methotrexate could be used as a second-line therapy, 
while mycophenolate mofetil and cyclosporine could be 
considered as third-line therapies, with the first one to be 
preferred over a long-term period because of the safer 
adverse effect profile with prolonged use. In our opinion, 
a short course of systemic steroids should be considered 
only to halt the progression and to improve symptoms in 
rapidly progressive and severe cases. When necessary, 
topical/intralesional steroids may be added to systemic 
therapies in the case of persistence of limited active areas. 
Interestingly, according to the results highlighted in this 
review, pioglitazone could be a promising and effective 
therapeutic option, although more evidence is needed to 
confirm its precise role in the LPP management. Based on 
available levels of evidence and success rates, we believe 
it could be considered as a third-line treatment, beside 
cyclosporine and mycophenolate mofetil. Figure 1 sum-
marizes the proposed treatment strategy.
Of note, it has to be kept in mind that the abovementioned 
therapeutic management is not the result of head-to-head 
comparisons, and treatment outcomes reported in the vari-
ous studies are quite variable. Therefore, it should be viewed 
with a critical eye and regarded as general advice which has 
to be adapted on case-by-case basis. Future randomized and 
controlled prospective studies are needed to better define the 
optimal therapeutic approach in LPP.
Disclosure
The authors report no conflicts of interest in this work.
Classic lichen planopilaris
Limited forms
Topical/intralesional
potent steroids Hydroxychloroquine
Methotrexate
Cyclosporine
Mycophenolate mofetil
Pioglitazone
First-line
Second-line
Third-line
Extensive forms*§
Figure 1 Proposed treatment strategy for classic lichen planopilaris.
Notes: *Topical/intralesional steroids may be added to systemic therapies in the case of persistence of limited active areas. §A short course of systemic steroids should be 
considered only to halt the progression and to improve symptoms in rapidly progressive and severe cases.
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